Navigation Links
DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
Date:6/7/2008

Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than Hemoglobin A1C of Exenatide, Sitagliptin, Pramlintide and Prandial Insulin

Therapies in Certain Diabetic Populations

SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today results from the ongoing DURABLE clinical trial showing that the GlycoMark blood test is a better reflection of glucose, particularly after-meal glucose levels, than the gold standard hemoglobin A1C test in moderately controlled patients with diabetes. These findings were reported by Kathleen Dungan, MD, of Ohio State University (Columbus, OH) and investigators from Eli Lilly (Indianapolis, IN) at the American Diabetes Association's 68th Annual Scientific Sessions (ADA) in San Francisco.

This is the largest clinical study to evaluate the clinical utility of GlycoMark to reflect after-meal glucose levels with 2,094 patients enrolled from 11 countries. The DURABLE trial (Assessing the Durability of Basal vs. Lispro Mix 75/25 Insulin Efficacy) confirms results from a smaller population study completed by John Buse, MD (University of North Carolina), Steven Wittlin, MD (University of Rochester), and Kathleen Dungan, MD, published in the medical journal Diabetes Care in June 2006.

In the study, the 1,5-Anhydroglucitol blood test (GlycoMark) correlated more strongly than hemoglobin A1C with all self-monitored plasma glucose (SMPG) parameters, particularly after-meal glucose levels, in moderately controlled patients with A1C levels less than 8.0%. Dr. Dungan concluded, "The data support the use of 1,5-anhydroglucitol, in conjunction with A1C, in moderately controlled patients with type 2 diabetes."

"This large clinical study validates the important role of the GlycoMark test to effectively monitor patients with diabetes," said Eric Button, President of GlycoMark, Inc. "Although patients may appear to be adequately controlled by A1C results, it may not readily revea
'/>"/>

SOURCE GlycoMark, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
4. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
5. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
10. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Neuralstem, Inc. (NYSE MKT: CUR), a ... small molecule and cell therapy treatments for central nervous ... Jones to the position of Chief Financial Officer, ... Lloyd Jones brings to the position more ... experience.   Most recently, Mr. Lloyd Jones served ...
(Date:5/6/2015)... 2015 AbbVie (NYSE: ABBV ) will ... Health Care Conference on Wednesday, May 13, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:5/6/2015)... , May 6, 2015   Symbiomix Therapeutics ... the third and final tranche of a $41 million ... randomized Phase 2 trial testing a single oral dose ... Based on discussions with the U.S. Food and Drug ... now is planning to submit the Phase 2 trial ...
Breaking Medicine Technology:Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 2Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 2Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 5
(Date:5/6/2015)... California (PRWEB) May 06, 2015 ... hand sanitizers are increasing, driven by the rising consumer ... the spread of contagious diseases. Hand washing is becoming ... of consumer apprehension over contracting infections. Periodic outbreak of ... the recent Ebola virus disease (EVD) epidemic ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 In March, ... at the 8th Milano Masterclass. As Europe’s most exclusive ... elite plastic surgeons. Dr. Batniji was hand chosen to ... Plastic and Reconstructive Surgery, Dr. Pietro Palma. , ... Italy. The conference hosts a diverse, multi-national faculty; each ...
(Date:5/6/2015)... AZ (PRWEB) May 06, 2015 The ... open for League Corporate Partner booth selection . ... and services to community college and university decision-makers from ... place November 1-4, 2015, at the Arizona Grand in ... private desert oasis on the doorstep of the South ...
(Date:5/6/2015)... GA (PRWEB) May 06, 2015 ... chosen Hexagon Geospatial technology to manage and distribute imagery, ... Australia is one of the driest continents on earth, ... through times of drought and erratic seasonal rainfalls has ... supply solutions. , Water NSW manages raw water supplies ...
(Date:5/6/2015)... The Florida Council on Compulsive Gambling, Inc. (FCCG), ... Area Geriatric Education Center, Mental Health Association of Southeast ... Substance Abuse, will hold its annual conference in Ft ... Hotel. , This important event will address topics such ... as clinical training for problem gambling treatment services. ...
Breaking Medicine News(10 mins):Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 3Health News:Growing Apprehension Amid Disease Outbreaks Drives Global Sales of Hand Sanitizers, According to a New Report by Global Industry Analysts, Inc. 4Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Conference on Problem Gambling to be held in Ft. Lauderdale, FL 2
... can a pediatric urologist researching intersexuality learn from a forensic ... own ways to make more informed decisions, but rarely do ... Now, for the first time, leading practitioners ... from national security, business, education, medicine, forensics and the law ...
... ... ... -- Advocate Health Care, a not-for-profit, faith-based health care system, today announced it provided ... than one-million lives touched in the communities it serves throughout Chicagoland and a substantial ...
... PICK: Identifying preterm infants at risk of life-threatening conditions ... to life-threatening conditions that are clinically difficult to detect. ... microbes are present in the blood, and necrotizing enterocolitis, ... But now, Terrence Poon and colleagues, at the The ...
... Leading Youth ... , ... -- O2 MAX Fitness , a youth fitness brand focused on addressing the unmet fitness ... unveil a whole new line of initiatives aimed at helping the college female this year. According ...
... ... fatigue syndrome” without the negative side effects of caffeine? Need to ... Energy, the caffeine- and sugar- free vegetarian capsules made of all ... may boost memory and drive metabolism, among other health benefits. PureStart ...
... July 1, 2010 The Damon Runyon Cancer ... Investigators at its April 2010 Clinical Investigator Award ... three-year award are outstanding early career physician-scientists conducting ... the mentorship of the nation,s leading scientists and ...
Cached Medicine News:Health News:Knowledge workers divulge trade secrets at Global Intelligence Forum 2Health News:Advocate Health Care Reports $462 Million in Community Benefits 2Health News:Advocate Health Care Reports $462 Million in Community Benefits 3Health News:JCI online early table of contents: July 1, 2010 2Health News:JCI online early table of contents: July 1, 2010 3Health News:JCI online early table of contents: July 1, 2010 4Health News:JCI online early table of contents: July 1, 2010 5Health News:JCI online early table of contents: July 1, 2010 6Health News:JCI online early table of contents: July 1, 2010 7Health News:Fighting Off the Freshman Fifteen 2Health News:Fighting Off the Freshman Fifteen 3Health News:DecafaLife, LLC Announces New All-Natural Product to Keep You Energized While Kicking Your Caffeine Habit 2Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 3Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 4Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 5Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 6
The HEP-1 system accommodates mini to full size gels with a transfer area of 20cmWx 20cmL, designed specifically for the transfer from polyacrylamide or agarose gels....
... from agarose gels to hybridization membranes in ... and efficiency of transfer by allowing high ... of an integrated system allowing electrophoresis, gel ... hours, versus 29 hours required for conventional ...
Trans-Blot Plus Gel/Cassette Assembly Tray...
A blotter fit for use with the incredible new Criterion precast gel system, the Criterion blotter combines excellent blotting efficiency with the flexibility of the Trans-Blot system and the ease-of-...
Medicine Products: